HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Natriuretic peptides in therapy for decompensated heart failure.

Abstract
Congestive heart failure (CHF) is the most frequent cause of hospitalization for patients >65 years of age and continues to be a major public health burden among the ageing population. Unlike therapy for chronic CHF, there has been only modest progress in medical treatment for acutely decompensated CHF over the past several decades. Moreover, current treatment-consisting generally of diuretic, inotropic, and vasodilatory agents-is associated with many limitations in clinical practice. Natriuretic peptides provide a promising mechanism of action in the pathophysiologic background for CHF treatment based on their vasodilatory and diuretic properties and effective inhibition of the renin-angiotensin-aldosterone system, which is activated early in the course of CHF. Nesiritide (Natrecor® or Noratak®) is a recombinant natriuretic peptide that has the same 32 amino-acid sequence as human B-type natriuretic peptide. Nesiritide has been shown to improve dyspnea and hemodynamic parameters in patients with decompensated heart failure. Ularitide is a synthetic form of urodilatin, a natriuretic peptide hormone secreted by the kidney. Recent clinical studies suggest that ularitide may play a role in managing decompensated heart failure. This review provides an update on natriuretic peptides and their therapeutic potential in advanced CHF.
AuthorsNatig Gassanov, Esther Biesenbach, Evren Caglayan, Amir Nia, Uwe Fuhr, Fikret Er
JournalEuropean journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 68 Issue 3 Pg. 223-30 (Mar 2012) ISSN: 1432-1041 [Electronic] Germany
PMID21901345 (Publication Type: Journal Article, Review)
Chemical References
  • Natriuretic Agents
  • Natriuretic Peptides
  • Recombinant Proteins
  • Vasodilator Agents
Topics
  • Heart Failure (drug therapy, metabolism, physiopathology)
  • Humans
  • Natriuretic Agents (therapeutic use)
  • Natriuretic Peptides (metabolism, therapeutic use)
  • Recombinant Proteins (therapeutic use)
  • Vasodilator Agents (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: